In its recent statement, Bharat Biotech has stated that during February-March this year, the Phase-1 clinical trials of its new intranasal antidote for the corona virus would start. Apart from Covaxin, Bharat Biotech has been vigorously working on making another vaccine. For the vaccine, it collaborated with Washington University School of Medicine in St Louis for the novel “chimp-adenovirus” (Chimpanzee adenovirus). According to a response to PTI, Bharat Biotech stated that the studies had been conducted in the USA and India. It further stated that the preclinical testing has been completed for toxicology, immunogenicity and challenge studies. According to Bharat Biotech, phase-1 human clinical trials will be conducted in India.
According to the company sources, the phase-1 trials will take place in Saint Louis University’s Vaccine and Treatment Evaluation Unit. It also added that Bharat Biotech owns the rights to allocate the vaccine in all markets apart from USA, Japan and Europe. According to the Chairman of Bharat Biotech – Krishna Ella – the company is emphasising on the intranasal vaccine. This is due to the fact the prevailing vaccines need two dose intramuscular injections. He had stated that a country like India requires 2.6 billion syringes and needles which may add up to pollution.
He had reasoned that an intranasal vaccine will not only be simple to administer but decrease the use of medical consumables such as needles, syringes, etc. This would help decrease the overall cost of a vaccination drive. He had stated that one drop of vaccine in each of the nostrils was enough.